MARKET

AGNPF

AGNPF

Algernon Pharmac
OTCMQB
0.058
NaN%
Closed 09:30 03/14 EDT
OPEN
--
PREV CLOSE
0.058
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.115
52 WEEK LOW
0.038
MARKET CAP
1.59M
P/E (TTM)
-4.1799
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AGNPF last week (0303-0307)?
Weekly Report · 4d ago
Netcapital to host planned Reg A offering by Algernon NeuroScience
TipRanks · 03/07 13:36
Algernon engages Netcapital Securities for Regulation A financing
TipRanks · 03/06 12:05
Weekly Report: what happened at AGNPF last week (0224-0228)?
Weekly Report · 03/03 10:41
Weekly Report: what happened at AGNPF last week (0217-0221)?
Weekly Report · 02/24 10:41
Weekly Report: what happened at AGNPF last week (0210-0214)?
Weekly Report · 02/17 10:39
Algernon Pharmaceuticals appoints Sandor Nardai as OI for Phase 2a DMT study
TipRanks · 02/11 12:16
Algernon NeuroScience Partners with Validcare for Pioneering Stroke Study
TipRanks · 02/10 18:32
More
About AGNPF
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Webull offers Algernon Pharmaceuticals Inc stock information, including OTCMQB: AGNPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGNPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGNPF stock methods without spending real money on the virtual paper trading platform.